Drug Trial Radar · NCT06975878
Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,092
Actual
Start
May 22, 2025
Primary completion
Aug 25, 2027
Study completion Aug 25, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 42 days, up to 112 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 15vPCV (Vaxneuvance, licensed pneumococcal conjugate vaccine) when they are administered with routine pediatric vaccines in infants aged from approximately 2 months (42 to 112 days). The study duration per participant will be up to approximately 20 months. The study vaccines (either PCV21 or 15-valent pneumococcal vaccines) will be administered at approximately 2, 4, and 11 to 15 months of age or at approximately 2, 3, 4, and 11 to 15 months of age (for preterm infants). Routine pediatric vaccines will be given at the same timepoints, as per local practice / recommendations. • There will be 5 (for full-term infants) or 6 (for preterm infants) study visits: * Full-term infants: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 30 days, V04 at 11 months of age until 15 months of age, V05 separated from V04 by 30 days. * Preterm infants: Visit (V)01, V02 separated from V01 by 30 days, V03 separated from V02 by 30 days, V04 separated from V03 by 30 days, V05 at 11 months of age until 15 months of age, V06 separated from V05 by 30 days.
Conditions
- Pneumococcal Immunization
- Healthy Volunteers
Interventions
PCV21 vaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Vaxneuvance vaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Hexyon vaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
M-M-RvaxPro vaccineBiological
Pharmaceutical form:Powder and solvent for suspension for injection-Route of administration:Intramuscular or Subcutaneous
Varivax vaccineBiological
Pharmaceutical form:Powder and solvent for suspension for injection-Route of administration:Intramuscular or Subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroresponse rate for PCV21 and 15vPCV serotypesTime frame: 30 days post-toddler dose
- IgG concentration for PCV21 and 15vPCV serotypesTime frame: 30 days post-toddler dose
Locations
49 sites in 8 countries. Site status is shown where the registry gives one.
Investigational Site Number : 0560004
Alken, Belgium
Investigational Site Number : 0560001
Bruges, Belgium
Investigational Site Number : 0560002
Edegem, Belgium
Investigational Site Number : 0560005
Gozée, Belgium
Investigational Site Number : 0560007
Leuven, Belgium
Investigational Site Number : 0560003
Roeselare, Belgium
Investigational Site Number : 2030001
Jindřichův Hradec, Czechia
Investigational Site Number : 2030009
Krnov, Czechia
Investigational Site Number : 2030006
Pilsen, Czechia
Investigational Site Number : 2030008
Prague, Czechia
Investigational Site Number : 2330001
Paide, Estonia
Investigational Site Number : 2330004
Tallinn, Estonia
Investigational Site Number : 2330002
Tartu, Estonia
Investigational Site Number : 2460008
Espoo, Finland
Investigational Site Number : 2460001
Helsinki, Finland
Investigational Site Number : 2460010
Helsinki, Finland
Investigational Site Number : 2460005
Jarvenpaa, Finland
Investigational Site Number : 2460003
Kokkola, Finland
Investigational Site Number : 2460004
Oulu, Finland
Investigational Site Number : 2460002
Seinäjoki, Finland
Investigational Site Number : 2460007
Tampere, Finland
Investigational Site Number : 2460009
Turku, Finland
Investigational Site Number : 2760005
Herxheim, Germany
Investigational Site Number : 2760006
Hürth, Germany
Investigational Site Number : 2760014
Hürth, Germany
Investigational Site Number : 2760013
Krefeld, Germany
Investigational Site Number : 2760010
Mönchengladbach, Germany
Investigational Site Number : 2760012
Mönchengladbach, Germany
Investigational Site Number : 2760008
Schönau am Königssee, Germany
Investigational Site Number : 2760003
Wolfsburg, Germany
Investigational Site Number : 3000001
Athens, Greece
Investigational Site Number : 3000002
Athens, Greece
Investigational Site Number : 3000006
Ioannina, Greece
Investigational Site Number : 3000005
Thessaloniki, Greece
Investigational Site Number : 3800001
Bari, Italy
Investigational Site Number : 3800008
Foggia, Italy
Investigational Site Number : 3800010
Lecce, Italy
Investigational Site Number : 3800007
Milan, Italy
Investigational Site Number : 3800009
Parma, Italy
Investigational Site Number : 3800004
Rome, Lazio, Italy
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.